Author:
Kiba Takayoshi,Inamoto Takashi,Nishimura Tsutomu,Ueno Masaya,Yanagihara Kazuhiro,Teramukai Satoshi,Kato Hironori,Toi Masakazu,Fukushima Masanori
Abstract
Abstract
Backgrounds
Prognostic factors are defined as biological or clinical measurement associated with overall survival and/or disease-free survival. Previous studies have shown that patients with estrogen receptor (ER) positive cancers have a better prognosis than patients whose cancers do not have these receptors.
Methods
This study investigated the assessment of variables in defining prognosis of 742 breast cancer women with pathological stage (pTNM) I-III diagnosed between 1980 and 2005 at the Kyoto University Hospital in Japan, by age, clinical stage (cTNM), pTNM, the numbers of positive lymph nodes (pN), and ER status.
Results
Multivariate analysis demonstrated that pTNM and ER status were the independent prognostic factors for overall survival, and that pTNM and pN were the independent prognostic factors for disease-free survival. For the 0- to 2-year interval, the hazard of recurrence was higher for the ER-negative patients than the ER-positive patients, and beyond 3 years the hazard was higher for ER-positive patients.
Conclusion
The present study confirmed the previous reports which showed favorable prognosis of the patients with lesser pTNM or positive ER status. A reversal of recurrence hazard rate between ER positive and negative breast cancer patients beyond 3 years after operation was detected. The fact may indicate the importance of long term adjuvant hormone therapy for ER positive cancer patients.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference15 articles.
1. DeVita VT, Hellman S, Rosenberg SA: Cancer: Principles and Practice of Oncology. 2001, Philadelphia: Lippincott Williams & Wilkins
2. Gospodarowicz M, Mackillop W, O'Sullivan B, Sobin L, Henson D, Hutter RV, Wittekind C: Prognostic factors in clinical decision making: the future. Cancer. 2001, 91 (8 Suppl): 1688-1695. 10.1002/1097-0142(20010415)91:8+<1688::AID-CNCR1184>3.0.CO;2-7.
3. Clark GM: Do we really need prognostic factors for breast cancer?. Breast Cancer Res Treat. 1994, 30 (2): 117-126. 10.1007/BF00666054.
4. Hedden S, Woolson R, Malcolm R: Randomization in substance abuse clinical trials. Substance Abuse Treatment, Prevention, and Policy. 2006, 1 (6): 1-17.
5. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ: 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007, 18 (7): 1133-1144. 10.1093/annonc/mdm271.
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献